Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
KalVista Pharmaceuticals, Inc.
KALV
$14.86
Name : KalVista Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $751,117,888.00
EPSttm : -3.94
finviz dynamic chart for KALV
KalVista Pharmaceuticals, Inc.
$14.86
9.10%
$1.24

Float Short %

35.16

Margin Of Safety %

Put/Call OI Ratio

1.45

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

1.27

Price

14.84

Target Price

31

Analyst Recom

1

Performance Q

16

Relative Volume

2.55

Beta

-0.16

Ticker: KALV




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20KALV11.540.260.008350
2025-10-21KALV11.430.260.088455
2025-10-22KALV11.140.250.178638
2025-10-23KALV11.010.250.068643
2025-10-24KALV11.110.250.068669
2025-10-27KALV11.250.250.508838
2025-10-28KALV11.10.250.008841
2025-10-29KALV10.940.250.018893
2025-10-30KALV10.980.250.018892
2025-10-31KALV10.90.240.538982
2025-11-03KALV10.810.254.939035
2025-11-04KALV10.770.270.059279
2025-11-05KALV10.980.279.119328
2025-11-06KALV10.90.909.0014755
2025-11-07KALV10.780.910.0014752
2025-11-10KALV10.90.910.0014754
2025-11-11KALV11.480.8540.9115311
2025-11-12KALV13.361.450.0120351
2025-11-13KALV13.111.450.0020350
2025-11-14KALV13.621.450.0020349
2025-11-17KALV14.851.450.0020357
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20KALV11.54-13.2- -3.70
2025-10-21KALV11.43-13.2- -3.70
2025-10-22KALV11.13-13.2- -3.70
2025-10-23KALV10.99-13.2- -3.74
2025-10-24KALV11.11-16.5- -3.79
2025-10-27KALV11.23-16.5- -3.79
2025-10-28KALV11.13-16.5- -3.79
2025-10-29KALV10.94-16.5- -3.79
2025-10-30KALV10.97-16.5- -3.79
2025-10-31KALV10.91-16.5- -3.79
2025-11-03KALV10.84-16.5- -3.79
2025-11-04KALV10.77-16.5- -3.79
2025-11-05KALV10.98-16.5- -3.79
2025-11-06KALV10.90-16.5- -3.79
2025-11-07KALV10.78-16.5- -3.79
2025-11-10KALV10.89-16.5- -3.79
2025-11-11KALV11.47-16.5- -3.79
2025-11-12KALV13.36-16.5- -3.79
2025-11-13KALV13.10-16.5- -3.79
2025-11-14KALV13.62-19.8- -4.06
2025-11-17KALV14.84-19.8- -4.06
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20KALV-1.09-1.0633.55
2025-10-21KALV-1.09-1.0633.55
2025-10-22KALV-1.09-1.0633.55
2025-10-23KALV-1.09-1.0633.55
2025-10-24KALV-1.09-1.0633.55
2025-10-27KALV-1.09-0.6738.29
2025-10-28KALV-1.09-0.6738.29
2025-10-29KALV-1.09-0.6738.29
2025-10-30KALV-1.09-0.6738.29
2025-10-31KALV-1.09-0.6738.29
2025-11-03KALV-1.09-0.5738.29
2025-11-04KALV-1.09-0.5738.29
2025-11-05KALV-1.09-0.5738.29
2025-11-06KALV-1.09-0.5738.29
2025-11-07KALV-1.09-0.5738.29
2025-11-10KALV-1.090.5038.42
2025-11-11KALV-1.080.5038.42
2025-11-12KALV-1.080.5035.32
2025-11-13KALV-1.110.5035.31
2025-11-14KALV-1.110.5035.05
2025-11-17KALV-1.135.6335.16
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-1.06

Avg. EPS Est. Next Quarter

-0.92

Insider Transactions

-1.13

Institutional Transactions

5.63

Beta

-0.16

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

14

Fair Value

Quality Score

19

Growth Score

25

Sentiment Score

77

Actual DrawDown %

67

Max Drawdown 5-Year %

-90.1

Target Price

31

P/E

Forward P/E

16.33

PEG

P/S

525.26

P/B

18.34

P/Free Cash Flow

EPS

-4

Average EPS Est. Cur. Y​

-4.06

EPS Next Y. (Est.)

-2.79

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-14242.57

Relative Volume

2.55

Return on Equity vs Sector %

-524.9

Return on Equity vs Industry %

-509.9

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.36

EBIT Estimation

KalVista Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 270
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today
news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance
stock history KALV – KalVista Pharmaceuticals Inc invest stock market
stock prices KALV premarket after hours
ticker KALV fair value insiders trading